London's biopharma-focused GHO Capital Partners claims close of largest-ever European fund
Three years after closing out its first €660 million ($730.5 million) private equity fund, London-based GHO Capital Partners has sealed a mammoth $1 billion-plus second fund, a feat it has claimed is the biggest-ever focused on European healthcare.
The investment firm has already injected capital into active pharmaceutical ingredient manufacturer Sterling Pharma Solutions and bioanalytical testing company BioAgilytix in the first quarter of 2019. GHO’s Fund II will invest in the outsourced services, pharma and medtech sectors, the company said on Wednesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,500+ biopharma pros reading Endpoints daily — and it's free.